Loading
A phase 2 trial of Gemcitabine in endometrial cancer, run by Acrivon Therapeutics, now recruiting.
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma is a phase 2 interventional study registered as NCT05548296 by Acrivon Therapeutics, with 350 participants planned, started 2022-08-29 and due to reach its primary completion in 2027-05-30. Interventions recorded: ACR-368 and Gemcitabine.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Shares Gemcitabine, Cytotoxic chemotherapy and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/